1 Barkley, R.A. Attention deficit hyperactivity disorder. A Handbook for Diagnosis and Treatment. 3rd ed. (Guilford, New York, 2006).

2 Swanson, J.M. et al. Etiologic subtypes of attention-deficit/hyperactivity disorder: brain imaging, molecular genetic and environmental factors and the dopamine hypothesis. Neuropsychol. Rev. 17, 39–59 (2007).

3 Bakker, S.C. et al. A whole-genome scan in 164 Dutch sib pairs with attention-deficit/hyperactivity disorder: suggestive evidence for linkage on chromosomes 7p and 15q. Am. J. Hum. Genet. 72, 1251–1260 (2003).

4 Fisher, S.E. et al. A genomewide scan for loci involved in attention-deficit/hyperactivity disorder. Am. J. Hum. Genet. 70, 1183–1196 (2002).

5 Ogdie, M.N. et al. Attention deficit hyperactivity disorder: fine mapping supports linkage to 5p13, 6q12, 16p13, and 17p11. Am. J. Hum. Genet. 75, 661–668 (2004).

6 Ogdie, M.N. et al. A genomewide scan for attention-deficit/hyperactivity disorder in an extended sample: suggestive linkage on 17p11. Am. J. Hum. Genet. 72, 1268–1279 (2003).

7 Zhou, K. et al. Meta-analysis of genome-wide linkage scans of attention deficit hyperactivity disorder. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 147B, 1392–1398 (2008).

8 Arcos-Burgos, M. et al. Attention-deficit/hyperactivity disorder in a population isolate: linkage to loci at 4q13.2, 5q33.3, 11q22, and 17p11. Am. J. Hum. Genet. 75, 998–1014 (2004).

9 Franke, B., Neale, B.M. & Faraone, S.V. Genome-wide association studies in ADHD. Hum. Genet. 126, 13–50 (2009).

10 Premont, R.T. et al. beta2-Adrenergic receptor regulation by GIT1, a G protein-coupled receptor kinase-associated ADP ribosylation factor GTPase-activating protein. Proc. Natl. Acad. Sci. USA 95, 14082–14087 (1998).

11 Claing, A. et al. Multiple endocytic pathways of G protein-coupled receptors delineated by GIT1 sensitivity. Proc. Natl. Acad. Sci. USA 97, 1119–1124 (2000).

12 Hoefen, R.J. & Berk, B.C. The multifunctional GIT family of proteins. J. Cell Sci. 119, 1469–1475 (2006).

13 Albertinazzi, C., Za, L., Paris, S. & de Curtis, I. ADP-ribosylation factor 6 and a functional PIX/p95–APP1 complex are required for Rac1B-mediated neurite outgrowth. Mol. Biol. Cell 14, 1295–1307 (2003).

14 Za, L. et al. betaPIX controls cell motility and neurite extension by regulating the distribution of GIT1. J. Cell Sci. 119, 2654–2666 (2006).

15 Segura, I., Essmann, C.L., Weinges, S. & Acker-Palmer, A. Grb4 and GIT1 transduce ephrinB reverse signals modulating spine morphogenesis and synapse formation. Nat. Neurosci. 10, 301–310 (2007).

16 Zhang, H., Webb, D.J., Asmussen, H., Niu, S. & Horwitz, A.F.A. GIT1/PIX/Rac/PAK signaling module regulates spine morphogenesis and synapse formation through MLC. J. Neurosci. 25, 3379–3388 (2005).

17 Zhang, H., Webb, D.J., Asmussen, H. & Horwitz, A.F. Synapse formation is regulated by the signaling adaptor GIT1. J. Cell Biol. 161, 131–142 (2003).

18 Menon, P. et al. Impaired spine formation and learning in GPCR kinase 2 interacting protein-1 (GIT1) knockout mice. Brain Res. 1317, 218–226 (2010).

19 Saneyoshi, T. et al. Activity-dependent synaptogenesis: regulation by a CaM-kinase kinase/CaM-kinase I/betaPIX signaling complex. Neuron 57, 94–107 (2008).

20 Kim, S. et al. The GIT family of proteins forms multimers and associates with the presynaptic cytomatrix protein Piccolo. J. Biol. Chem. 278, 6291–6300 (2003).

21 Ko, J. et al. Interaction between liprin-alpha and GIT1 is required for AMPA receptor targeting. J. Neurosci. 23, 1667–1677 (2003).

22 Schmalzigaug, R. et al. Impaired fear response in mice lacking GIT1. Neurosci. Lett. 458, 79–83 (2009).

23 Goehler, H. et al. A protein interaction network links GIT1, an enhancer of huntingtin aggregation, to Huntington's disease. Mol. Cell 15, 853–865 (2004).

24 Barkley, R.A. Behavioral inhibition, sustained attention, and executive functions: constructing a unifying theory of ADHD. Psychol. Bull. 121, 65–94 (1997).

25 Gilden, D.L. & Hancock, H. Response variability in attention-deficit disorders. Psychol. Sci. 18, 796–802 (2007).

26 Castellanos, F.X. & Tannock, R. Neuroscience of attention-deficit/hyperactivity disorder: the search for endophenotypes. Nat. Rev. Neurosci. 3, 617–628 (2002).

27 Russell, V.A. Reprint of “Neurobiology of animal models of attention-deficit hyperactivity disorder.” J. Neurosci. Methods 166, I–XIV (2007).

28 Gainetdinov, R.R. et al. Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity. Science 283, 397–401 (1999).

29 Hess, E.J., Collins, K.A. & Wilson, M.C. Mouse model of hyperkinesis implicates SNAP-25 in behavioral regulation. J. Neurosci. 16, 3104–3111 (1996).

30 Barry, R.J., Clarke, A.R. & Johnstone, S.J. A review of electrophysiology in attention-deficit/hyperactivity disorder: I. Qualitative and quantitative electroencephalography. Clin. Neurophysiol. 114, 171–183 (2003).

31 Düzel, E., Penny, W.D. & Burgess, N. Brain oscillations and memory. Curr. Opin. Neurobiol. 20, 143–149 (2010).

32 Uhlhaas, P.J. & Singer, W. Abnormal neural oscillations and synchrony in schizophrenia. Nat. Rev. Neurosci. 11, 100–113 (2010).

33 Clarke, A.R., Barry, R.J., Bond, D., McCarthy, R. & Selikowitz, M. Effects of stimulant medications on the EEG of children with attention-deficit/hyperactivity disorder. Psychopharmacology (Berl.) 164, 277–284 (2002).

34 Feng, Q., Albeck, J.G., Cerione, R.A. & Yang, W. Regulation of the Cool/Pix proteins: key binding partners of the Cdc42/Rac targets, the p21-activated kinases. J. Biol. Chem. 277, 5644–5650 (2002).

35 Chavrier, P. & Goud, B. The role of ARF and Rab GTPases in membrane transport. Curr. Opin. Cell Biol. 11, 466–475 (1999).

36 Donaldson, J.G. Multiple roles for Arf6: sorting, structuring, and signaling at the plasma membrane. J. Biol. Chem. 278, 41573–41576 (2003).

37 Daly, G., Hawi, Z., Fitzgerald, M. & Gill, M. Mapping susceptibility loci in attention deficit hyperactivity disorder: preferential transmission of parental alleles at DAT1, DBH and DRD5 to affected children. Mol. Psychiatry 4, 192–196 (1999).

38 LaHoste, G.J. et al. Dopamine D4 receptor gene polymorphism is associated with attention deficit hyperactivity disorder. Mol. Psychiatry 1, 121–124 (1996).

39 Bokoch, G.M. Biology of the p21-activated kinases. Annu. Rev. Biochem. 72, 743–781 (2003).

40 Boda, B., Nikonenko, I., Alberi, S. & Muller, D. Central nervous system functions of PAK protein family: from spine morphogenesis to mental retardation. Mol. Neurobiol. 34, 67–80 (2006).

41 Meyer, D.K. et al. Regulation of somatodendritic GABAA receptor channels in rat hippocampal neurons: evidence for a role of the small GTPase Rac1. J. Neurosci. 20, 6743–6751 (2000).

42 Cobos, I., Borello, U. & Rubenstein, J.L. Dlx transcription factors promote migration through repression of axon and dendrite growth. Neuron 54, 873–888 (2007).

43 Richter, K. et al. Presynaptic cytomatrix protein bassoon is localized at both excitatory and inhibitory synapses of rat brain. J. Comp. Neurol. 408, 437–448 (1999).

44 Barkley, R.A. A review of stimulant drug research with hyperactive children. J. Child Psychol. Psychiatry 18, 137–165 (1977).

45 Rosa-Neto, P. et al. Methylphenidate-evoked changes in striatal dopamine correlate with inattention and impulsivity in adolescents with attention deficit hyperactivity disorder. Neuroimage 25, 868–876 (2005).

46 Südhof, T.C. Neuroligins and neurexins link synaptic function to cognitive disease. Nature 455, 903–911 (2008).

47 Tabuchi, K. et al. A neuroligin-3 mutation implicated in autism increases inhibitory synaptic transmission in mice. Science 318, 71–76 (2007).

48 Deutsch, S.I., Rosse, R.B., Schwartz, B.L. & Mastropaolo, J. A revised excitotoxic hypothesis of schizophrenia: therapeutic implications. Clin. Neuropharmacol. 24, 43–49 (2001).

49 Fernandez, F. et al. Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome. Nat. Neurosci. 10, 411–413 (2007).

50 Kleschevnikov, A.M. et al. Hippocampal long-term potentiation suppressed by increased inhibition in the Ts65Dn mouse, a genetic model of Down syndrome. J. Neurosci. 24, 8153–8160 (2004).

51 Costa, R.M. et al. Mechanism for the learning deficits in a mouse model of neurofibromatosis type 1. Nature 415, 526–530 (2002).

52 Cui, Y. et al. Neurofibromin regulation of ERK signaling modulates GABA release and learning. Cell 135, 549–560 (2008).

53 Shilyansky, C. et al. Neurofibromin regulates corticostriatal inhibitory networks during working memory performance. Proc. Natl. Acad. Sci. USA 107, 13141–13146 (2010).

54 Kalanithi, P.S. et al. Altered parvalbumin-positive neuron distribution in basal ganglia of individuals with Tourette syndrome. Proc. Natl. Acad. Sci. USA 102, 13307–13312 (2005).

55 Moll, G.H., Heinrich, H. & Rothenberger, A. Methylphenidate and intracortical excitability: opposite effects in healthy subjects and attention-deficit hyperactivity disorder. Acta Psychiatr. Scand. 107, 69–72 (2003).

56 Moll, G.H., Heinrich, H., Trott, G., Wirth, S. & Rothenberger, A. Deficient intracortical inhibition in drug-naive children with attention-deficit hyperactivity disorder is enhanced by methylphenidate. Neurosci. Lett. 284, 121–125 (2000).

57 Richter, M.M., Ehlis, A.C., Jacob, C.P. & Fallgatter, A.J. Cortical excitability in adult patients with attention-deficit/hyperactivity disorder (ADHD). Neurosci. Lett. 419, 137–141 (2007).

58 Pouget, P., Wattiez, N., Rivaud-Pechoux, S. & Gaymard, B. A fragile balance: perturbation of GABA mediated circuit in prefrontal cortex generates high intraindividual performance variability. PLoS ONE 4, e5208 (2009).

59 Kaufman, J. et al. Schedule for Affective Disorders and Schizophrenia for School-Age Children—Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. J. Am. Acad. Child Adolesc. Psychiatry 36, 980–988 (1997).